Industry Trends

Clinical Research
Off-shoring: A Country Attractiveness Index for Clinical Trials

By Mark P. Mathieu
For many years, pharmaceutical companies have been off-shoring manufacturing operations to lower-cost countries. Healthy margins and strong risk aversion have afforded pharmaceutical companies the luxury of staying close to home, for all but manufacturing activities. As financial pressures increase, pharmaceutical executives are finding that going offshore is not only less risky than it once was, but also too attractive to ignore.  Read More




PHT Scales for Global ePRO Business by Updating StudyWorks



By Ann Neuer

January 19, 2010 | With the market for electronic patient report outcomes (ePRO) heating up, ePRO provider PHT Corporation is launching a significantly updated version of StudyWorks, its online portal. Sheila Rocchio, vice president of marketing, says that the portal’s expanded capabilities are designed to accommodate the sector’s growth, fueled by the December release of a final PRO guidance by the Food and Drug Administration (FDA). Several sections of the guidance are devoted to ePRO.

“We know that 25 percent of studies are now including PRO, and we believe that of those studies, approximately 25 percent are adopting ePRO. This is a global figure, and we are expecting that number to rise, especially with the final guidance now in place,” Rocchio says.

To handle the anticipated upswing in the sector, the StudyWorks portal has come to market with several new features. The most significant is the inventory reports meant to reduce the challenge of tracking ePRO devices such as SitePad, which resides at the investigative site; and LogPad, which is distributed to study volunteers.

“This is the biggest change StudyWorks offers. The reports allow study coordinators, monitors, project mangers and administrators to get an up-to-date view of where the hardware is for any study. A major issue that people perceive with ePRO is that is it logistically difficult to manage and track all of the devices on a global basis, and pharma does not want to be in the hardware business. There is a movement away from ownership and toward a management model,” says Anne Pelz, manager of product management.

Pelz explains that as trials become increasingly global, stakeholders have had to make sure that devices arrive on time at the proper locations. The revised StudyWorks relieves the site and sponsor of that burden by including tracking numbers for shipping, the number of devices at each site, and those that are still in inventory. As soon as a subject is enrolled, the system assigns a device to the individual and computes how many are left. If the site enrolls more subjects than expected, it can request more hardware through the Study Support Center, and all of this information is tracked in StudyWorks.

The ability to create real-time inventory reports is the result of PHT’s recent implementation of the Oracle e-Business system. Rocchio explains, “We know when devices are shipped and received. All of the ordering is done in the Oracle system.” Prior to this implementation and integration with StudyWorks, customers received weekly updates on the details of the usage patterns of their devices. Now, sponsors can simply pull up this information.
 
In addition to the inventory reports, the upgraded portal boasts a number of other elements. First, sites and sponsors can see ePRO data from SitePad and LogPad more quickly as StudyWorks offers transparency through real-time, 24/7 access to data collected from both devices. Next, there are improvements to e-mail alerts, which serve several purposes. They are used to advise the study personnel as to patient compliance issues or if a patient reported outcome signals intervention. Improvements come in the form of fewer clicks needed for the site to access the data that generated the e-mail alert. For example, in an asthma study, if a score worsens over a period of time, the site is notified and getting to that information is easier for the study personnel. And with this information, the site can alert the patient.

Sites are also notified by e-mail alert if they have failed to enter information, yet the subject continues to make entries. “This can be caught in a number of ways—in screening or in treatment,” Pelz comments.

Currently, approximately 45 studies are using the upgraded StudyWorks portal, and benefiting from the new features. More will come on board as customers deploy new studies.

Rocchio says that the new features are in response to customer feedback, and reflect PHT’s strategy of listening to its customers to consistently improve services that help them better manage their clinical trials.

Click here to log in.

0 Comments

Add Comment

Text Only 2000 character limit

Page 1 of 1

White Papers & Special Reports

Life Science Webcasts & Podcasts

medidata podcast #8 Meeting Today’s Challenges in Clinical Trial Supply Management
Sponsored by: Medidata Solutions Worldwide  

Setting up and managing the clinical trial involves many complex procedures. Among the most challenging are planning and executing the logistics of the trial’s clinical supplies. This podcast focuses in depth on the following topics which trace current practices and future evolution of this crucial aspect of clinical trials:

  • Current practices in clinical trial logistics
  • Comparing advances in clinical supply practices to  other aspects of clinical trials 
  • Where current practices fall short of meeting the challenges
  • Trends and evolving improvements that may change the way logistics are conducted

Listen Now  


More Podcasts

Job Openings

tessella logo 
Scientific Software Engineer
Boston MA
$70,000 to $95,000
 

Tessella delivers software engineering and consulting services to leading pharmaceutical and biotech companies. We are recruiting Software Engineersto work with skilled bioinformaticians and scientists to identify business needs and recommend and develop technical solutions. Applicants require BS, MS or PhD in bioinformatics, biology or chemistry and 2+ years of software development in either: Java, C#, C++, C or VB.NET. 

Apply at http://jobs.tessella.com   

 

oxford nanopore logo 


 Early Access Collaborations Managers
Oxford Nanopore Technologies is developing a novel technology, GridIONTM for the direct, electronic analysis of DNA/RNA and other analytes.  As the system approaches the market, we are building a team of technically knowledgeable, highly motivated candidates with excellent customer service and facilitation skills to join our company as Collaboration Managers.  This is a unique opportunity to work with world-leading genomics customers throughout the early adoption phase of a new generation of DNA sequencing technology.. This is a facilitative, enabling role with responsibility for managing technology development collaborations with key customers at leading genomics institutions.  It will include long term management of the collaboration plan and milestones and associated meetings and documentation. Click here to find out more and apply   

Oxford Nanopore's GridION technology, VP, Sales and Marketing Oxford Nanopore Technologies is a fast-moving technology company that is developing a novel electronic molecular analysis technology. The technology is adaptable for the analysis of DNA/RNA, proteins, chemicals and other molecules.  It is therefore suitable for use in a variety of markets including scientific research and clinical applications.  As the technology approaches the market, Oxford Nanopore is seeking a visionary VP of sales and marketing to join the senior team.  The candidate will embrace the opportunities afforded by entering the market with a truly disruptive technology that has the potential to expand the number of users and the variety of applications in each target market.  This is a rare opportunity to influence the commercial strategy at an early phase of its commercial lifetime, in a well funded company.  Oxford Nanopore welcomes applications from candidates with a track record of high-level strategic commercial  leadership, who wish to apply a fresh approach to existing markets.  Experience in Life Sciences/DNA sequencing is central to this role, however we will consider your application if you have experience of disruptive technologies in other related industries.  We are particularly interested in candidates with strong expertise in the use of digital technologies for sales and marketing of scientific/technical products.  Click to  Apply  


 





Sponsored Links

For reprints and/or copyright permission, please contact  Tim McLucas, (781) 972-1342, tmclucas@healthtech.com .